已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Cytarabine Dose for Acute Myeloid Leukemia

阿糖胞苷 医学 依托泊苷 化疗 诱导化疗 米托蒽醌 外科 养生 内科学 胃肠病学
作者
Bob Löwenberg,Thomas Pabst,Edo Vellenga,Wim van Putten,Harry C. Schouten,Carlos Graux,Augustin Ferrant,Pieter Sonneveld,Bart J. Biemond,Alois A. Gratwohl,Georgine E. de Greef,Leo F. Verdonck,Martijn R. Schaafsma,Michael Gregor,Matthias Theobald,Urs Schanz,Johan A. Maertens,Gert Jan Ossenkoppele
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:364 (11): 1027-1036 被引量:407
标识
DOI:10.1056/nejmoa1010222
摘要

BACKGROUND: Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated. METHODS: We compared two induction regimens in patients 18 to 60 years of age (median, 49) who had newly diagnosed AML. The intermediate-dose group, totaling 431 patients, received cytarabine at a dose of 200 mg per square meter given by continuous intravenous infusion for 24 hours during cycle 1 of induction therapy and 1000 mg per square meter by infusion for 3 hours twice daily during cycle 2 of induction therapy. The high-dose group, totaling 429 patients, received a dose-escalated regimen of 1000 mg of cytarabine per square meter every 12 hours in cycle 1 and 2000 mg per square meter twice daily in cycle 2. Patients with a complete response did not receive additional cytarabine but received consolidation therapy in a third cycle of chemotherapy (mitoxantrone-etoposide) or underwent autologous or allogeneic stem-cell transplantation. Complete remission rates, survival rates, and toxic effects were assessed for each treatment group. RESULTS: At a median follow-up of 5 years, no significant differences were noted between the intermediate-dose group and the high-dose group with respect to complete remission rates (80% and 82%, respectively), probability of relapse, event-free survival at 5 years (34% and 35%), or overall survival (40% and 42%). High-dose cytarabine provided no clear advantage in any prognostic subgroup. The high-dose treatment resulted in higher incidences of grade 3 and grade 4 toxic effects (in cycle 1), prolonged hospitalization, and delayed neutrophil recovery (in cycle 2) and platelet recovery (in cycles 2 and 3). CONCLUSIONS: Induction therapy with cytarabine at the lower dose already produced maximal antileukemic effects for all response end points, suggesting a plateau in the dose-response relationship above this dose level. High-dose cytarabine results in excessive toxic effects without therapeutic benefit. (Netherlands Trial Register number, NTR230.).

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
英俊的铭的应助被李宇彤采纳,获得10
2秒前
小鱼发布了新的文献求助10
2秒前
isssstwice完成签到 ,获得积分10
2秒前
小二郎的应助被vc采纳,获得10
2秒前
贪玩的采白完成签到 ,获得积分10
4秒前
4秒前
suijinicheng完成签到 ,获得积分10
4秒前
5秒前
爱你老己完成签到 ,获得积分10
5秒前
5秒前
虚掩的门发布了新的文献求助10
6秒前
深情安青的应助被呼呼呼采纳,获得10
6秒前
不懂科研的小刘完成签到,获得积分10
7秒前
作业本的应助被wonderfulwisdom采纳,获得10
7秒前
8秒前
雪莉完成签到 ,获得积分10
9秒前
9秒前
9秒前
小蘑菇的应助被潇洒的代双采纳,获得10
9秒前
鹅鹅发布了新的文献求助10
9秒前
9秒前
yuri发布了新的文献求助10
10秒前
11秒前
林子完成签到,获得积分10
11秒前
lizrt完成签到 ,获得积分10
11秒前
LuXiaoyu的应助被玄牝采纳,获得10
12秒前
13秒前
斯文明杰发布了新的文献求助10
13秒前
drizzle发布了新的文献求助10
15秒前
林子发布了新的文献求助10
15秒前
15秒前
xxxxyyy完成签到,获得积分10
16秒前
16秒前
LuXiaoyu的应助被含蓄大雁采纳,获得10
18秒前
20秒前
21秒前
丘比特的应助被whz采纳,获得10
22秒前
Crssss的应助被零可林采纳,获得30
23秒前
xinyuanjia的应助被hfhkjh采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179198
求助须知:如何正确求助?哪些是违规求助? 9569781
关于积分的说明 21806509
捐赠科研通 7774542
什么是DOI,文献DOI怎么找? 3433008
关于科研通互助平台的介绍 2556929
邀请新用户注册赠送积分活动 2478652